Safety and Tolerability of Patisiran (ALN-TTR02) in Transthyretin (TTR) Amyloidosis

Clinical trial NCT01617967 · COMPLETED

Trial details

NCT number: NCT01617967
Sponsor: Alnylam Pharmaceuticals
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

TTR-mediated Amyloidosis

Start date: 2012-05-01
Primary completion: 2013-10-01
Enrollment: 29

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.